157 related articles for article (PubMed ID: 6225458)
1. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II).
Eastman A
Biochemistry; 1983 Aug; 22(16):3927-33. PubMed ID: 6225458
[No Abstract] [Full Text] [Related]
2. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.
Eastman A
Biochemistry; 1986 Jul; 25(13):3912-5. PubMed ID: 3741840
[TBL] [Abstract][Full Text] [Related]
3. Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.
Eastman A
Biochemistry; 1985 Sep; 24(19):5027-32. PubMed ID: 4074675
[TBL] [Abstract][Full Text] [Related]
4. Analysis and quantitation of the DNA damage produced in cells by the cisplatin analog cis-[3H]dichloro(ethylenediamine)platinum (II).
Eastman A
Anal Biochem; 1991 Sep; 197(2):311-5. PubMed ID: 1785684
[TBL] [Abstract][Full Text] [Related]
5. Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation.
Fichtinger-Schepman AM; Lohman PH; Reedijk J
Nucleic Acids Res; 1982 Sep; 10(17):5345-56. PubMed ID: 6216456
[TBL] [Abstract][Full Text] [Related]
6. Repair of cis-platinum-DNA adducts by ABC excinuclease in vivo and in vitro.
Husain I; Chaney SG; Sancar A
J Bacteriol; 1985 Sep; 163(3):817-23. PubMed ID: 3897194
[TBL] [Abstract][Full Text] [Related]
7. Modulation of platinum antitumor drug binding to DNA by linked and free intercalators.
Bowler BE; Lippard SJ
Biochemistry; 1986 May; 25(10):3031-8. PubMed ID: 3718938
[TBL] [Abstract][Full Text] [Related]
8. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
Plooy AC; van Dijk M; Lohman PH
Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808
[TBL] [Abstract][Full Text] [Related]
9. DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].
Brabec V; Vrána O; Nováková O; Kleinwächter V; Intini FP; Coluccia M; Natile G
Nucleic Acids Res; 1996 Jan; 24(2):336-41. PubMed ID: 8628659
[TBL] [Abstract][Full Text] [Related]
10. Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II).
Mascharak PK; Sugiura Y; Kuwahara J; Suzuki T; Lippard SJ
Proc Natl Acad Sci U S A; 1983 Nov; 80(22):6795-8. PubMed ID: 6196777
[TBL] [Abstract][Full Text] [Related]
11. Chromatographic analysis of the adducts formed in DNA complexed with cis-diamminedichloroplatinum(II).
Rahn RO
J Inorg Biochem; 1984 Aug; 21(4):311-21. PubMed ID: 6332878
[TBL] [Abstract][Full Text] [Related]
12. Deoxyribonuclease I footprinting reveals different DNA binding modes of bifunctional platinum complexes.
Chválová K; Kaspárková J; Farrell N; Brabec V
FEBS J; 2006 Aug; 273(15):3467-78. PubMed ID: 16824042
[TBL] [Abstract][Full Text] [Related]
13. Effects of second-generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo.
Mong S; Huang CH; Prestayko AW; Crooke ST
Cancer Res; 1980 Sep; 40(9):3318-24. PubMed ID: 7191777
[TBL] [Abstract][Full Text] [Related]
14. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
16. Excretion kinetics of the DNA adducts of cis-diamminedichloroplatinum(II) formed in vitro in rat urine.
Försti A; Takala M; Laatikainen R; Hemminki K
Carcinogenesis; 1988 Oct; 9(10):1745-8. PubMed ID: 3168153
[TBL] [Abstract][Full Text] [Related]
17. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
Fichtinger-Schepman AM; van der Veer JL; den Hartog JH; Lohman PH; Reedijk J
Biochemistry; 1985 Jan; 24(3):707-13. PubMed ID: 4039603
[TBL] [Abstract][Full Text] [Related]
18. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
19. Diamine ligand release from the cisplatin analogue [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) in cell culture medium.
Bednarski PJ; Trümbach B; Kratochwil NA; Schönenberger H
J Med Chem; 1992 Nov; 35(23):4479-85. PubMed ID: 1447748
[TBL] [Abstract][Full Text] [Related]
20. Binding of cis- and trans-diamminedichloroplatinum(II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies.
Sundquist WI; Lippard SJ; Stollar BD
Biochemistry; 1986 Apr; 25(7):1520-4. PubMed ID: 3707890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
